3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Sarcoma, Clear Cell
1
Rectal Neoplasms
1
Radiation-induced Oral Mucositis
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Platinum-resistant Epithelial Ovarian Cancer
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Anatomic Stage I Breast Cancer AJCC v8
1
Adenocarcinoma of Lung
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Leucovorin
6
Irinotecan
6
Gemcitabine
5
fludarabine
3
aldesleukin
3
Pemetrexed
3
Nivolumab
3
Cyclophosphamide
3
Cetuximab
3
Capecitabine
3
5,10-methylenetetrahydrofolic acid
3
dehydroftorafur
2
cobimetinib
2
Specimen Handling
2
Panitumumab
2
Interleukin-2
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tivozanib
1
sodium propionate
1
rucaparib
1
rilotumumab
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gastrointestinal Neoplasms
×
Hydroxychloroquine
×
Clear all
NCT04214418
2024-12-18
MEKiAUTO
Columbia University
Phase 1/2
Terminated
27 enrolled
12 charts